Tony Matzouranis
Corporate Officer/Principal chez BELLUS HEALTH
Profil
Tony Matzouranis is currently the Chief Business Officer at BELLUS Health, Inc. Prior to his current position, he worked as the Licensing Director at Thallion Pharmaceuticals, Inc. from 2007 to 2010.
Mr. Matzouranis holds a graduate degree from Université du Québec à Montréal.
Postes actifs de Tony Matzouranis
| Sociétés | Poste | Début |
|---|---|---|
| BELLUS HEALTH | Corporate Officer/Principal | 01/01/2010 |
Anciens postes connus de Tony Matzouranis
| Sociétés | Poste | Fin |
|---|---|---|
| THALLION PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/02/2010 |
Formation de Tony Matzouranis
| Université du Québec à Montréal | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
Thallion Pharmaceuticals, Inc.
 Thallion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thallion Pharmaceuticals, Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its products are Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli bacterial infections and TLN-4601, a proprietary first in class small molecule with potential efficacy in multiple oncology indications. The company was founded in January 1998 and is headquartered in Dorval, Canada. | Health Technology |
